Protagonist Therapeutics Commercialized Peptide Drug
The company successfully launched a pill-form drug for psoriasis after years of developing oral peptide technology.
Updated on Sept. 26, 2026 in Biotech
Live Poll
Do you believe the shift toward oral pill-form medications will make chronic disease treatment more affordable?
Protagonist Therapeutics has successfully commercialized Icotyde, a pill-form peptide drug for psoriasis that launched earlier this year. This milestone follows the FDA approval of their second peptide treatment, Mimrylo, granted in August 2026.
Why it matters
Traditional peptide drugs are typically destroyed by the digestive system, requiring patients to rely on injections. Protagonist Therapeutics developed proprietary technology to engineer gut-stable peptides, potentially transforming how these treatments are administered.
Protagonist Therapeutics currently holds a market value of nearly $9 billion, with stock value having doubled in the past year. The company receives royalties ranging from 6% to 10% on global Icotyde sales.
The players
Protagonist Therapeutics
This biotechnology company focuses on the development of oral peptide drugs to replace traditional injectable treatments.
AbbVie
This global biopharmaceutical company manufactures Skyrizi, a leading medication in the psoriasis treatment market.
Novo Nordisk
This multinational pharmaceutical corporation is currently developing its own oral versions of peptide-based medications.
The details
The firm creates gut-stable peptides by modeling them after closed-loop venom structures, which are chemically modified to survive stomach acid. This platform allows for oral delivery, an advancement that has drawn significant attention from industry competitors.
Timeline
In 2025, the Wall Street Journal reported that Johnson & Johnson considered acquiring Protagonist Therapeutics.
Icotyde launched commercially earlier this year.
The FDA approved the company's second drug, Mimrylo, in August 2026.
The Tech Race
The rise of Protagonist Therapeutics follows the wider industry trend toward converting injectable peptide treatments into oral formats, similar to the development of oral versions of Wegovy by Novo Nordisk. This shift represents a major departure from legacy systems that previously required invasive injections.
Patients may eventually see a shift away from traditional, invasive injection therapies toward more convenient pill-based treatments for chronic conditions like psoriasis. This transition could lower the barrier to treatment adherence and improve daily medication routines.
The takeaway
The successful commercialization of oral peptides marks a major milestone in pharmaceutical delivery innovation. Patients and clinicians should monitor how these new oral delivery platforms compare to traditional treatments in terms of long-term efficacy and costs.
Further reading
Learn more about the latest industry developments in the Biotech section.
Source note: This article includes information reported by Tovima.
Live Poll
Do you believe the shift toward oral pill-form medications will make chronic disease treatment more affordable?
